OraSure’s MIRIAD results
This article was originally published in The Gray Sheet
Executive Summary
OraQuick rapid HIV test use in point-of-care labor and delivery settings allows an average 45 minute turn-around time - more than four times faster than the 3.5 hour average needed when the same test is performed in a lab, according to CDC's Maternal Infant Rapid Intervention at Delivery study. Started in November 2001, MIRIAD tested 380 women in Chicago with 100% accuracy, finding and treating three who were HIV positive. OraQuick was approved by FDA in November 2002. CDC's previous purchase of 250,000 of the tests will be finalized in January (1"The Gray Sheet" June 30, 2003, In Brief)...
You may also be interested in...
OraSure OraQuick
CDC commits to purchase of 250,000 rapid HIV-1 antibody tests for $2 mil. by Dec. 31 for 50 U.S. locations. Approved in November 2002 and CLIA-waived in January, the test will be used in CDC's HIV testing and prevention initiative. The Bethlehem, Penn. firm donated tests to eight sites for "national HIV testing day" June 27...
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.